Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 223,200 shares, an increase of 42.3% from the May 15th total of 156,900 shares. Based on an average daily volume of 2,505,100 shares, the short-interest ratio is presently 0.1 days.
Bayer Aktiengesellschaft Stock Performance
Shares of Bayer Aktiengesellschaft stock traded down $0.13 on Friday, hitting $7.24. 287,468 shares of the company traded hands, compared to its average volume of 1,136,538. The firm’s 50-day simple moving average is $7.52 and its 200 day simple moving average is $7.97. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.31. Bayer Aktiengesellschaft has a 12-month low of $6.96 and a 12-month high of $14.70.
Bayer Aktiengesellschaft (OTCMKTS:BAYRY – Get Free Report) last posted its quarterly earnings data on Tuesday, May 14th. The company reported $0.77 earnings per share for the quarter. The firm had revenue of $14.95 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. On average, analysts expect that Bayer Aktiengesellschaft will post 1.36 EPS for the current year.
Bayer Aktiengesellschaft Cuts Dividend
Wall Street Analysts Forecast Growth
BAYRY has been the topic of several research reports. The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They issued a “neutral” rating on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, March 7th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, February 29th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.
Read Our Latest Report on BAYRY
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.
Featured Stories
- Five stocks we like better than Bayer Aktiengesellschaft
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 6/10 – 6/14
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- NYSE Stocks Give Investors a Variety of Quality Options
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Bayer Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.